BR112013023722A2 - métodos para prever o risco de um indivíduo ter ou desenvolver uma coença, e para diagnosticar um indivíduo com uma doença, kit, modelo de animal não humano, e, sistema para identificar lóbulos coriocapilares aberrantes - Google Patents

métodos para prever o risco de um indivíduo ter ou desenvolver uma coença, e para diagnosticar um indivíduo com uma doença, kit, modelo de animal não humano, e, sistema para identificar lóbulos coriocapilares aberrantes

Info

Publication number
BR112013023722A2
BR112013023722A2 BR112013023722A BR112013023722A BR112013023722A2 BR 112013023722 A2 BR112013023722 A2 BR 112013023722A2 BR 112013023722 A BR112013023722 A BR 112013023722A BR 112013023722 A BR112013023722 A BR 112013023722A BR 112013023722 A2 BR112013023722 A2 BR 112013023722A2
Authority
BR
Brazil
Prior art keywords
individual
disease
methods
coriocapillary
lobes
Prior art date
Application number
BR112013023722A
Other languages
English (en)
Inventor
Christian Matthew Pappas
Giuliana Silvestri
Gregory Hageman
Monika Fleckenstein
Pulina Haas
Robin Guymer
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of BR112013023722A2 publication Critical patent/BR112013023722A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

métodos para prever o risco de um indivíduo ter ou desenvolver uma coença, e para diagnosticar um indivíduo com uma doença, kit, modelo de animal não humano, e, sistema para identificar lóbulos coriocapilares aberrantes são aqui descritos métodos e composições para o diagnóstico e tratamento de maculopatia vascular associada, ou um sintoma da mesma, em um indivíduo. aqui são descritos métodos e composições para o diagnóstico e tratamento de um ou mais sintomas associados com maculopatia vascular associada descrita em um indivíduo. aqui são descritos métodos e composições para o diagnóstico e tratamento de maculopatia grave ou maculopatia de último estágio de um indivíduo. aqui são descritos métodos e composições para o diagnóstico e tratamento de esclarecer lóbulos coriocapilares aberrantes em um indivíduo.
BR112013023722A 2011-03-15 2012-03-15 métodos para prever o risco de um indivíduo ter ou desenvolver uma coença, e para diagnosticar um indivíduo com uma doença, kit, modelo de animal não humano, e, sistema para identificar lóbulos coriocapilares aberrantes BR112013023722A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161452964P 2011-03-15 2011-03-15
US201161452944P 2011-03-15 2011-03-15
US201161452950P 2011-03-15 2011-03-15
PCT/US2012/029299 WO2012125869A1 (en) 2011-03-15 2012-03-15 Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof

Publications (1)

Publication Number Publication Date
BR112013023722A2 true BR112013023722A2 (pt) 2016-11-22

Family

ID=46831104

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013023724A BR112013023724A2 (pt) 2011-03-15 2012-03-15 métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
BR112013023722A BR112013023722A2 (pt) 2011-03-15 2012-03-15 métodos para prever o risco de um indivíduo ter ou desenvolver uma coença, e para diagnosticar um indivíduo com uma doença, kit, modelo de animal não humano, e, sistema para identificar lóbulos coriocapilares aberrantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112013023724A BR112013023724A2 (pt) 2011-03-15 2012-03-15 métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento

Country Status (11)

Country Link
US (6) US20140303013A1 (pt)
EP (2) EP2686007B1 (pt)
JP (2) JP2014510526A (pt)
KR (2) KR20140026410A (pt)
CN (2) CN103562408A (pt)
AU (3) AU2012229067A1 (pt)
BR (2) BR112013023724A2 (pt)
CA (2) CA2830407C (pt)
RU (2) RU2013145890A (pt)
SG (2) SG193499A1 (pt)
WO (2) WO2012125872A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
SG194235A1 (en) * 2011-04-29 2013-12-30 Univ Utah Res Found Methods of predicting the development of complement-mediated disease
KR20150083117A (ko) * 2012-11-08 2015-07-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US20180245155A1 (en) * 2015-09-03 2018-08-30 Stephen T. McGarvey Compositions and Methods for Identifying Genetic Predisposition to Obesity and for Enhancing Adipogenesis
KR102343004B1 (ko) * 2015-12-03 2021-12-24 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
CN109715207B (zh) * 2016-03-29 2023-03-31 南加利福尼亚大学 靶向癌症的嵌合抗原受体
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
EP3472149B1 (en) 2016-06-21 2023-08-30 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
CA3072847A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
CN109563084A (zh) * 2016-08-23 2019-04-02 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型三氟甲基丙酰胺衍生物
JP2018096930A (ja) * 2016-12-16 2018-06-21 公益財団法人ヒューマンサイエンス振興財団 加齢黄斑変性の診断マーカー、診断キット、診断補助方法、及び、発症リスク判定方法
CN110234760A (zh) * 2016-12-22 2019-09-13 第一三共株式会社 用于治疗年龄相关性黄斑变性的肽
IL269363B2 (en) * 2017-03-16 2024-02-01 Lineage Cell Therapeutics Inc Methods for measuring medical effects of treating retinal diseases
WO2018183216A1 (en) * 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Notch3 agonist compositions and methods for treating small vessel diseases
CN107022611B (zh) * 2017-04-05 2020-07-31 李爱娟 一种用于检测4种常见临床心脑血管疾病药品精准用药的方法及专用引物
ES2870106T3 (es) 2017-05-05 2021-10-26 Zealand Pharma As Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
US20200243170A1 (en) * 2017-10-17 2020-07-30 Apeliotus Technologies, Inc. Functional biomarkers for statin therapy in age-related macular degeneration (amd)
CA3085211A1 (en) * 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Companion diagnostic for htra1 rna antagonists
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TW202015718A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 視網膜色素變性治療用胜肽
WO2020130121A1 (ja) * 2018-12-21 2020-06-25 株式会社クレスコ 眼科診断装置
CN109738387A (zh) * 2018-12-29 2019-05-10 佛山科学技术学院 一种基于吲哚箐绿的光学相干层析成像方法和装置
CN109886946B (zh) * 2019-02-18 2023-05-23 广州视源电子科技股份有限公司 基于深度学习的早期老年性黄斑病变弱监督分类方法
CN113966401A (zh) * 2019-04-10 2022-01-21 犹他大学研究基金会 用于治疗amd的htra1调节
CN111374937B (zh) * 2019-10-11 2023-04-18 郑州儿童医院 一种用于婴幼儿血管瘤凝胶及其制备方法
CN113817812A (zh) * 2020-06-18 2021-12-21 南京腾辰生物科技有限公司 一种蛋白酶基因甲基化作为脑卒中早期诊断的潜在标志物
US20220125383A1 (en) * 2020-10-23 2022-04-28 Diagnosys LLC Methods and apparatus for removing artifacts from an electroretinogram
CN112970666B (zh) * 2021-02-04 2023-02-03 复旦大学附属眼耳鼻喉科医院 一种简便式动物近视诱导装置及制作方法
RU2758662C1 (ru) * 2021-03-19 2021-11-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ определения показаний к антиангиогенной терапии при подозрении на влажную форму возрастной макулярной дегенерации

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (pt) 1968-10-17 1970-08-24
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5723289A (en) 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5869641A (en) 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5780228A (en) 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5846713A (en) 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US6028186A (en) 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
WO1996009792A1 (en) * 1993-05-17 1996-04-04 The Johns Hopkins University Improved visualization of choroidal blood flow and aberrant vascular structures in the eye
US5935942A (en) * 1994-12-14 1999-08-10 Zeimer; Ran Selective and non-invasive visualization or treatment of vasculature
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
DE69637805D1 (de) 1995-06-07 2009-02-26 Gilead Sciences Inc Nukleinsäure liganden die dna-polymerase binden und inhibieren
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US5898221A (en) 1996-09-27 1999-04-27 Sanyo Electric Company, Ltd. Semiconductor device having upper and lower wiring layers
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
JP4828670B2 (ja) * 1996-10-28 2011-11-30 千寿製薬株式会社 眼循環障害改善剤
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU776511B2 (en) * 1999-02-18 2004-09-09 Baylor University Compositions and methods for use in targeting vascular destruction
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
US6867349B2 (en) 2000-07-31 2005-03-15 Regents Of The University Of Minnesota Inhibition of gene expression using polynucleotide analogues
ES2728168T3 (es) 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
US20040064057A1 (en) * 2002-07-31 2004-04-01 Massachusetts Institute Of Technology Measuring circulating blood volume through retinal vasculometry
AU2005244958A1 (en) * 2004-05-20 2005-12-01 Vegenics Limited Method for inhibiting angiogenesis and/or lymphangiogenesis
DK2044223T3 (da) * 2006-07-26 2012-10-08 Univ Yale Inc Diagnosticering og behandling af aldersrelateret makuladegeneration
EP2081596A4 (en) * 2006-10-06 2010-07-21 Univ Utah Res Found METHOD FOR DETECTING DISEASES AND PATHOLOGICAL DISEASES OF IL AND TREATMENT THEREOF
CN101173314B (zh) * 2006-10-18 2010-12-01 四川省医学科学院（四川省人民医院） 检测老年黄斑变性疾病的试剂盒
WO2008103299A2 (en) * 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
US20100196935A1 (en) * 2007-03-12 2010-08-05 Mayo Foundation For Medical Education And Research Treating pre-eclempsia and cardiovascular diseases
WO2008137107A1 (en) * 2007-05-02 2008-11-13 Krouse Andrew J Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
TW200911290A (en) * 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
CN101550451B (zh) * 2008-03-04 2011-08-31 四川省医学科学院（四川省人民医院） 检测老年黄斑变性疾病的试剂盒
CN101857899A (zh) * 2009-04-03 2010-10-13 四川省医学科学院（四川省人民医院） 老年黄斑变性疾病的检测试剂盒

Also Published As

Publication number Publication date
CA2830403A1 (en) 2012-09-20
EP2686007A2 (en) 2014-01-22
CA2830407C (en) 2021-08-31
WO2012125872A3 (en) 2013-01-10
AU2017279757A1 (en) 2018-01-25
KR20140024321A (ko) 2014-02-28
CN103841991A (zh) 2014-06-04
EP2686007B1 (en) 2019-04-24
WO2012125872A2 (en) 2012-09-20
RU2013145890A (ru) 2015-04-20
BR112013023724A2 (pt) 2019-09-24
RU2013145892A (ru) 2015-04-20
SG193500A1 (en) 2013-10-30
US20200237861A1 (en) 2020-07-30
US20230233645A1 (en) 2023-07-27
WO2012125869A1 (en) 2012-09-20
KR20140026410A (ko) 2014-03-05
CA2830407A1 (en) 2012-09-20
AU2012229070A1 (en) 2013-10-31
JP2014515012A (ja) 2014-06-26
JP2014510526A (ja) 2014-05-01
EP2686446A1 (en) 2014-01-22
US20140323413A1 (en) 2014-10-30
US20180296637A1 (en) 2018-10-18
US20210353712A1 (en) 2021-11-18
AU2012229067A1 (en) 2013-10-31
EP2686007A4 (en) 2015-04-01
CN103841991B (zh) 2018-03-27
SG193499A1 (en) 2013-10-30
AU2012229070B2 (en) 2017-09-28
EP2686446A4 (en) 2014-08-27
US20140303013A1 (en) 2014-10-09
CN103562408A (zh) 2014-02-05

Similar Documents

Publication Publication Date Title
BR112013023722A2 (pt) métodos para prever o risco de um indivíduo ter ou desenvolver uma coença, e para diagnosticar um indivíduo com uma doença, kit, modelo de animal não humano, e, sistema para identificar lóbulos coriocapilares aberrantes
BR112012022943A2 (pt) inibidores de syk de imidazopiridnas
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
WO2012174282A3 (en) Biomarker compositions and methods
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
BRPI0906550A2 (pt) Métodos de determinação, polipeptídeo, método ara identificar um ou mais membros da familia tlp, agente isolado, métodos de identificar ou detectar um ou mais membros da família tlp e de modular a função e/ou atividade do sistema imune, anticorpos anti-tigit, métodos de modular uma interação de cd226-pvr, de modular uma função e/ou atividade de células imunes, de inibir uma resposta imune, de aumentar ou estimular uma resposta imune, de modular o tipo e/ou a quantidade da produção de citocina, de estimular a fosforilação de erk, de diagnosticar uma doença, de avaliar a gravidade de uma doença, de prevenir uma doença e de tratar ou diminuir a gravidade de uma doença.
BR112013002112A2 (pt) composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição
WO2014193999A3 (en) Biomarker methods and compositions
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
BR112014002975A2 (pt) composições de biomarcador e métodos
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
BR112014016251A2 (pt) composições e métodos para modificação da flora gastrointestinal
BR112014025189A2 (pt) prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica
BR112014011758A2 (pt) composição farmacêutica, proteína de fusão, polinucleotídeo, vetor, célula isolada, métodos para produzir uma proteína de fusão, para tratar ou previnir uma doença ou condição, para diagnosticar a suscetibilidade de um indivíduo a desenvolver uma doença ou condição, para determinar uma adequabilidade do indivíduo para ingressar em um experimento de classificação dedroga, e para identificar um agente, uso de uma combinação, e, combinação.
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2011100396A3 (en) Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
BRPI0920170A2 (pt) métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
WO2013090259A3 (en) Egfr and par2 regulation of intestinal permeability
WO2014169011A3 (en) Methods for treating immune diseases
BR112012028010A2 (pt) anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
WO2011158016A3 (en) Assay
BR112013000566A2 (pt) composições e métodos para o aumento da capacidade de eclosão de aves e prévio desempenho

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]